Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Gary Gilliland

Showing results (1-10 of 177) with videos related to

Pageof 18
Sort By:
Best Practice & Research. Clinical Haematology|August 26, 2003
FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitorsD Gary Gilliland
Cell|November 26, 2003
Proteolytic processing in development and leukemogenesisD Gary Gilliland
Seminars in Hematology|November 26, 2002
Molecular genetics of human leukemias: new insights into therapyD Gary Gilliland
Mayo Clinic Proceedings|July 13, 2005
The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosisAyalew Tefferi, D Gary Gilliland
Cell Cycle (Georgetown, Tex.)|March 14, 2007
Oncogenes in myeloproliferative disordersAyalew Tefferi, D Gary Gilliland
Cell Cycle (Georgetown, Tex.)|June 23, 2005
JAK2 in myeloproliferative disorders is not just another kinaseAyalew Tefferi, D Gary Gilliland
Cell Stem Cell|March 7, 2009
A radical bailout strategy for cancer stem cellsZuzana Tothova, D Gary Gilliland
Cancer Cell|October 7, 2008
Going with the flow: JAK-STAT signaling in JMMLDemetrios Kalaitzidis, D Gary Gilliland
Newsweek|December 27, 2005
Your health in the 21st century. Do stem cells cause cancer?D Gary Gilliland, Tom Fagan
Cell Stem Cell|March 29, 2008
FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic systemZuzana Tothova, D Gary Gilliland
Pageof 18

Showing results (1-10 of 177) with videos related to

Sort By:
Pageof 18
Best Practice & Research. Clinical Haematology|August 26, 2003
FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitorsD Gary Gilliland
Cell|November 26, 2003
Proteolytic processing in development and leukemogenesisD Gary Gilliland
Seminars in Hematology|November 26, 2002
Molecular genetics of human leukemias: new insights into therapyD Gary Gilliland
Mayo Clinic Proceedings|July 13, 2005
The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosisAyalew Tefferi, D Gary Gilliland
Cell Cycle (Georgetown, Tex.)|March 14, 2007
Oncogenes in myeloproliferative disordersAyalew Tefferi, D Gary Gilliland
Cell Cycle (Georgetown, Tex.)|June 23, 2005
JAK2 in myeloproliferative disorders is not just another kinaseAyalew Tefferi, D Gary Gilliland
Cell Stem Cell|March 7, 2009
A radical bailout strategy for cancer stem cellsZuzana Tothova, D Gary Gilliland
Cancer Cell|October 7, 2008
Going with the flow: JAK-STAT signaling in JMMLDemetrios Kalaitzidis, D Gary Gilliland
Newsweek|December 27, 2005
Your health in the 21st century. Do stem cells cause cancer?D Gary Gilliland, Tom Fagan
Cell Stem Cell|March 29, 2008
FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic systemZuzana Tothova, D Gary Gilliland
Pageof 18